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OBJECTIVES: HCV infection in Egypt is one of the highest in the World. The objective 
of the study is to support Egyptian decision makers by comparing different treat-
ment rates with the recent approved Hep C antiviral agents, and its implications on 
prevalence progress and associated costs. METHODS: The analysis was based on 
a 17-year Markov model.Patients would progress through the various HCV stages 
from F0 to F3 followed by cirrhosis. Following cirrhosis to other progressive stages 
up to hepatocellular carcinoma and liver related death. Patients could be cured 
spontaneously in state F0 or as a result of antiviral therapy in any state from F0 to 
cirrhosis at a cure rate of 92% in stages F0-F3 and a cure rate of 80% in the stage of 
cirrhosis. Cured patients would transition to the mortality risk of the age-matched 
general population. In each cycle, new incident patients were also introduced at a 
rate of approximately 128,000 or 2%. RESULTS: Treating 8% of the infected cases 
each year (450K viremic cases/year) would bring the prevalence to 1 million by 2030. 
A treatment rate of 1% (65Kcases/yr) or 5% (300Kcases/yr) would bring the preva-
lence to 5.5 million and 2.5 million respectively by 2030. Total annual costs would 
start at $1.3Billion in the first year of treatment for the 8% treatment rate but would 
decrease to $580million/yr by 2030. The 5% and 1% rates would start at $900million 
& $550million. CONCLUSIONS: A treatment rate of 450Kcases/yr would bring the 
prevalence to 1 million by 2030. Costs would be significantly high during the first 
5 years, but eventually would dop as the disease burden decreases. Alternative 
scenarios wouldn’t eliminate the disease by 2030. A screening policy need to be 
in place & health infrastructure assessed in preparation for the rising numbers of 
patients receiving treatment
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OBJECTIVES: To determine (1) the cost of hospitalization and 1-week post-dis-
charge, (2) the difference between estimated costs and the Philippine Health 
Insurance Corporation (PhilHealth) pneumonia case rate payments, and (3) the 
economic burden of community-acquired pneumonia (moderate and high-risk, 
CAP-MR and CAP-HR, respectively) among patients aged > 19 years old in the 
Philippines. METHODS: The study involved two tertiary private hospitals in the 
Philippines. Using the societal perspective, out-of-pocket expenses and productivity 
losses were computed. A base case and sensitivity analyses were performed and the 
economic burden of pneumonia was determined using Philhealth claims. RESULTS: 
The estimated cost of hospitalization for CAP-MR was PhP 36,153 - 113,633 (US$852 
– 2,678) and the1-week post-discharge cost for CAP-MR was PhP 1,450 – 8,800 (US$ 
34 – 207) The cost of hospitalization for CAP-HR was PhP 104,544 – 249,695 (US$2,464 
– 5,885) and PhP 101,248 – 243, 495 (US$2,386 – 5,739) with the use of either invasive 
ventilation or non-invasive ventilation, respectively. The post discharge cost for 
CAP-HR was PhP 1,716 – 10,529 (US$40 – 248). In comparison, the present PhilHealth 
case rate payments for CAP-MR is PhP 15,000 (US$354) and PhP 32,000 (US$754) 
for CAP-HR. Based on the number of PhilHealth claims for the year 2012 and the 
study results, the economic burden of pneumonia in 2012 was PhP 8.48 billion for 
CAP-MR and PhP 643.76 million for CAP-HR. CONCLUSIONS: The paper reported the 
hospitalization and follow-up costs of CAP-MR and CAP-HR based on the societal 
perspective. It showed significant difference from the current case rate payments 
of the Philippine Health Insurance Corporation.
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OBJECTIVES: While it is known that accurate and timely diagnosis and treatment of 
infections can present a major healthcare challenge, there is a lack of in-depth studies 
examining infection diagnosis and treatment practices and their associated costs in 
large real-world patient populations. The study objective was to examine infection 
prevalence, current diagnosis and treatment practices, and costs associated with 
managing patients with infections via retrospective analysis of a large US electronic 
health record database. METHODS: Patients with infections were identified based 
on the use of antimicrobial therapy for > 24 h following hospital admission. Infection 
type was identified using ICD-9 diagnosis coding. Patients were classified into four 
groups: (1) pneumonia, (2) sepsis without pneumonia, (3) other infectious etiology, 
and (4) non-infectious etiology initially suspected as infectious. Illness severity was 
assessed using the Acute Physiology Score. Diagnostic procedures and treatments 
were identified via ICD-9 procedure coding and pharmacy order data, respectively. 
Per-patient cost estimates ($USD), calculated over 15 days from admission, encom-
passed diagnostic tests, radiologic procedures, and antimicrobial and other pharma-
ceutical treatments. RESULTS: In total, 127,174 patient visits met inclusion criteria. 
Pneumonia was the most common infection type (20.1% of visits), followed by other 
infectious etiology (16.0%) and sepsis without pneumonia (7.0%). Non-infections ini-
tially suspected as infections represented 56.9% of visits. Overall, 62.5% of patients 
had medium or high illness severity. Length-of-stay was > 5 days for 49.2% of patients. 
Bacterial tests accounted for 92.4% of diagnostic tests, and antibiotics accounted 
for the majority (> 98%) of antimicrobial treatments. Suspected infections with non-
infectious etiology had the highest per-patient costs for low-severity ($14,228) and 
medium-severity patients ($12,551). For high-severity patients, pneumonia carried the 
highest per-patient cost ($14,541). CONCLUSIONS: This study demonstrates that the 
total costs (in 2014 US dollars) were estimated for each urgent ABR threat, for each 
year analyzed. RESULTS: The number of CRE- and C. diff-related hospitalizations 
increased during the study period (CRE: 109,304 in 2001 to 692,680 in 2012; C. diff: 
144,312 in 2001 to 359,395 in 2012) but decreased for N. gonorrhoeae (5,440 in 2001 
to 4,130 in 2012). The mean LOS for all hospitalizations in the US between 2001-
2012 was 4.58 days and mean per-patient cost of $16,168. LOS for all urgent threats 
decreased over time (LOS: N. gonorrhoeae, 2001: 4.05 days, 2012: 3.92 days; CRE, 2001: 
10.15 days, 2012: 6.98 days; and C. diff, 2001: 13.53 days, 2012: 10.41 days) while total 
costs increased for N. gonorrhoeae, (2001: $9,963, 2012: $14,675) and C. diff(2001: 
$36,896, 2012: $43,632) but not for CRE (2001: $27,356, 2012: $26,959). CONCLUSIONS: 
Although LOS among ABR-related hospitalizations in the US has decreased over 
time, costs for both N. gonorrhoeae and C. diff have increased, +47% and +18%, 
respectively. Future efforts to reduce the incidence of ABR infection will improve 
the public’s health as well as decrease the associated economic burden.
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OBJECTIVES: To describe direct medical costs and factors associated with 
three disease stages of chronic hepatitis B virus infection (CHB) in Guangzhou, 
China. METHODS: We conducted a retrospective cohort study of patients with 
CHB using a hospital information system database from 2008 to 2012 in the larg-
est specialized infection hospital in Guangdong Province, China. Average annual 
costs and cost components were calculated. Generalized estimating equations were 
applied to explore associations between factors and costs. All costs were adjusted 
to RMB in 2012 at a discounting rate of 5% per year. RESULTS: A total of 65,792 (58 
455 outpatients and 7 337 inpatients) were involved in the analysis. Number of 
visits/admissions (mean) per case per year for outpatient and inpatient were as 
follows: CHB: 4.56/1.12; Cirrhosis: 4.34/1.24; HCC: 2.46/1.13; and the correspond-
ing average costs per person-time were: CHB: 581.79 and 8994.90 RMB; Cirrhosis: 
670.71 and 16574.44 RMB; HCC: 643.69 and 20900.89 RMB, respectively. Antiviral 
(47.93%) and non-antiviral medicines (34.44%, including 16.99% of liver protec-
tors and 6.31% of traditional Chinese medicine) for outpatient were the main cost 
components. Inpatient non-antiviral medicine and lab test contributed 45.56% and 
23.38% of total costs; but antiviral medicine was only at 6.28% of total costs. Male, 
elder, antiviral patients, cirrhosis and HCC patients had statistically significant 
higher costs as compared with female, younger, non-antiviral and CHB patients. 
Among the outpatients, self-payment patients’ costs were the highest, followed by 
patients with medical insurance and free medical service, whereas opposite effect 
direction on costs was found in inpatients, and the differences were statistically 
significant. CONCLUSIONS: Direct medical costs of inpatients with CHB increase 
significantly as the disease progresses. Payment mode has different effect direc-
tion between outpatient and inpatient, indicating that reimbursement policy for 
clinic and hospitalized patients have an important role on direct medical costs in 
treating HBV.
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OBJECTIVES: To assess the burden of and identify predictors of hospitalization costs 
associated with adverse drug events (ADEs) related to anti-infectives that were 
present on admission (POA) in US hospitals. Furthermore, we sought to identify dif-
ferences in costs by gender and age groups. METHODS: Using the 2012 Nationwide 
Inpatient Sample, we identified ADEs associated with anti-infectives using diagnosis 
codes (ICD-9-CM) and E codes. Differences in average and median hospitalization 
costs between subgroups were assessed using t-tests and Wilcoxon non-parametric 
median tests. To assess predictors of cost, we developed a generalized linear model 
(GLM) using the Modified Park test, Box-Cox regression test, Akaike information 
criterion and residual analysis to improve model fit. Results were weighted to obtain 
nationally representative cost estimates in 2012 dollars. RESULTS: Our study identi-
fied 49,623 discharges with POA ADEs (national estimate= 248,095) associated with 
anti-infectives with a total cost of $2.1 billion (national estimate= $10.6 billion). The 
mean cost for each hospitalization was $43,499 (SD= $76,865, median= $23,565, 
interquartile range= $13,189-$45,424) with a range $275 to $2,995,306. The mean 
length of stay (LOS) was 6.64 days (SD= 7.84, median= 5) and ranged from 0 to 354 
days. Total hospitalization costs were significantly (p= < .0001) higher for males 
(4.50%) and those aged 65 years or older (3.34%). GLM with gamma family and log 
link was a better model compared to ordinary least-squares. Using this model, we 
identified several significant cost predictors: LOS, age at admission, race, gender, 
median household income, hospital bed size and numerous comorbidities. Our 
model estimated that the cost of hospitalization, which was $67,528 for LOS of 
one day, increased 11.20% with each day increase in LOS. Each year increase in age 
caused 0.05% increase in hospitalization costs. CONCLUSIONS: Our findings sug-
gest that ADEs associated with anti-infectives are more costly when they occur in 
older patients and among those with medical comorbidities.
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(by R$1,011) and effectiveness (by 2.7%) were greater compared to VAN, resulting in 
an ICER of R$37,564 per successfully treated patients. But compared to TEI, LZD had 
lower costs (by R$2,246) and greater effectiveness (by 13.3%), with LZD being the 
‘dominating’ treatment. Majority of treatment costs were related to hospital stay, 
primarily ICU (73% in private and 50% in public scenario). Several scenarios were 
tested by varying treatment duration (7or14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). Results for all scenarios were similar to the base 
case from public and private perspectives. CONCLUSIONS: From private perspective 
LZD is a cost-effective alternative to VAN and TEI for treatment of MRSA-confirmed 
NP, owing primarily to its higher clinical response rate. From public perspective, LZD 
can be considered cost effective since its ICER vs. VAN is within 2-3 times Brazil’s 
GDP per capita.
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OBJECTIVES: The objective of the review was to determine the most widely used 
estimates of United States (US) costs of different stages of liver disease in patients 
with hepatitis C virus (HCV) in cost-effectiveness analyses (CEA). METHODS: A 
systematic literature search using predetermined search terms was performed 
to identify English-language articles that report cost or CEA from 1995 to 2014. 
Full texts were obtained and reviewed to determine study eligibility on the basis 
of predefined inclusion and exclusion criteria. All costs were inflated to 2014 
values. RESULTS: A total of 53 articles were eligible for review. In primary cost 
studies, two methods were generally used to derive the disease state costs: 
microcosting using treatment algorithms and unit costs; or statistical analyses 
of observational databases. The most widely used primary cost estimates in CEAs 
completed before 2011 were those derived using treatment algorithms by Bennett 
and colleagues (1997). A CEA published in 2012 by Gellad and colleagues presented 
updated resource use and costs for all the disease stages based on the Bennett 
study and added mild/moderate chronic HCV, compensated cirrhosis, and post-
SVR health states. The most widely used primary cost estimates in CEAs completed 
after 2012 are those obtained from a large database study by McAdam-Marx and 
colleagues (2011). This study provides estimates for all liver stages but does not 
include subcategories for decompensated disease. The estimates from the dif-
ferent sources were quite different; for example, for cirrhosis and hepatocellular 
carcinoma Gellad estimated $745 and $45,728 per year while McAdam-Marx esti-
mated $2,584 and $50,658 per year, respectively. CONCLUSIONS: There are many 
estimates of costs of HCV liver disease and these estimates can vary widely due 
to differences in study methodology. Understanding the differences in these esti-
mates can aid in the selection of the most appropriate inputs for use in economic 
models.
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OBJECTIVES: AASLD/IDSA have recently updated their treatment guidelines to 
include sofosbuvir-based therapy as recommended regimen for treatment-naïve and 
previously treated patients with hepatitis C (HCV) genotype 1 infection. The purpose 
of the study was to compare the cost-effectiveness of sofosbuvir-based combination 
therapies vs. peg-IFN and ribavirin (PEGIFN) among treatment-naïve patients and 
compare sofosbuvir-based combinations with and without interferon among patients 
previously treated with PEGIFN. METHODS: Cost per sustained viral response (SVR) 
was performed using a decision tree. It was assumed that patients were equally likely 
to receive either treatment. The model contained clinical data from Phase III clinical 
trials for PEGIFN (T1), sofosbuvir triple therapy (T2) (NEUTRINO study), and sofos-
buvir plus simeprevir and/or ribavirin (T3) (COSMOS study); drug and medical costs 
were obtained from the National Average Drug Acquisition Costs Database (Medicaid) 
and literature. Time horizon was 48 weeks for both analyses. RESULTS: Average cost 
among the treatment-naïve was $79,749 for T1 arm (52% SVR), $101,317 for T2 (91% 
SVR), and $147,386 for T3 (94% SVR). Among the pre-treated, the average cost was 
$142,862 for T2 (72% SVR) and $187,664 for T3 (94% SVR). Among the treatment-naïve, 
an ICER of $553 and $719 per 1%SVR gain was obtained for T2 vs. T1 and T3 vs. T1, 
respectively. Among the pre-treated, an ICER of $2036 per 1%SVR was obtained for T3 
vs. T2. In sensitivity analysis, no other factor but %SVR impacted incremental costs 
per responder. CONCLUSIONS: Although sofosbuvir-based combination without 
interferon was found to be the most expensive treatment it achieved the highest 
SVR rates among treatment-naive and pre-treated patients. The presented results 
can be used to make decisions by individual payers’ based on their willingness to pay 
thresholds. Future studies should examine the cost-effectiveness of new therapies 
by relevant HCV patient subgroups.
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OBJECTIVES: A 2010 randomized controlled trial, the first in the United States (US), 
was carried out to study the clinical effectiveness of pre-exposure HIV prophylaxis 
(PrEP) among men-who-have-sex-with-men (MSM) population over a follow up of 
diagnosis and treatment of hospitalized patients with infections carries a significant 
cost and suggests potential benefits in reducing time to diagnosis.
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OBJECTIVES: Malaria treatment in health care facility represents a standard prac-
tice in malaria case management. The study estimated the costs of treatment for 
uncomplicated malaria from a healthcare facility, to generate current information 
for appropriate decision making in resource or funding allocations for malaria 
treatment and control in Nigeria. METHODS: Based on a comprehensive cost of 
illness approach, hospital associated costs of uncomplicated malaria episodes 
were estimated from a provider perspective, applying a standard costing procedure 
for outpatient services. Capital and recurrent expenditures were estimated using 
ingredient approach combined with step-down methodology to calculate the final 
costs. Costs attributable to malaria treatment were calculated based on the propor-
tion of uncomplicated malaria cases treated within in the period. Non-hospital 
costs were not collected. Total and average financial and economic costs were 
estimated for uncomplicated malaria. All costs were calculated in local currency, 
converted to the US Dollars at the 2013 exchange rate. RESULTS: The hospital 
spent a total annual economic cost of N31.612 million (US$201,352.30) for the treat-
ment of uncomplicated malaria, at US$34.66 per case. This represents about 20% of 
the hospital total expenditure within the year. Personnel accounted for over 81% of 
the expenditure as the dominant cost driver, followed by antimalarial drugs, 7.8%. 
Over 45% of outpatients visits were treated for malaria in the facility, leading to 
increased utilization of hospital resources. Changes in personnel costs, drug prices 
and malaria prevalence significantly impacted on the study results, indicating the 
need for improved efficiency in the hospital resource utilization. CONCLUSIONS: 
Malaria treatment at the medical center constitutes a considerable amount of 
hospital expenditure, arising mainly from the cost of personnel and high propor-
tion of malaria treatment. For a more effective healthcare system, there is need 
for more efficient use of hospital resources to prevent wastages and reduce costs 
to the provider and consumer.
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OBJECTIVES: This study sought to estimate the average outpatient cost of providing 
adult antiretroviral therapy (ART) at an urban care centre for the ﬁrst year following 
ART initiation. METHODS: A retrospective, ingredients-based costing approach was 
implemented, as previously described in literature. Medical records for a conveni-
ent sample of 120 patients were reviewed 1 year after ART initiation. Subjects were 
assigned to any one of the following outcome categories based on their status at 
the end of the study period: in care and responding (IC); in care but not responding 
(NR); or no longer in care at study site (NIC). Average cost per outcome category 
was estimated based on resource utilisation, in 2013 US$. RESULTS: The overall 
annual retention in care was 93.3%. At the end of the first 12 months of ART care, 
109 (90.8%) of the patients were IC, 7 (6.7%) patients were NIC and 3 (2.5%) patients 
were NR. The average outpatient cost per patient initiated was USD $461. The costs 
were structured as follows; outpatient visits (49.2%), medications (26.4%), laboratory 
tests (21.8%) and fixed costs (2.6%). The average cost to produce an IC patient was 
US$ 472, NR US$ 438 and NIC US$ 322. The average cost of producing a patient in 
care and responding to ART represented 49.2% of the country’s GDP per capita for 
2013. This estimate excludes building and utility costs because they were unavail-
able, hence the actual average cost may be higher. CONCLUSIONS: These findings 
show that maintaining an HIV/AIDS patient in care and responding to ART is an 
expensive undertaking relative to the country’s GDP per capita. This underscores 
the need for periodic costing studies as a way of continually monitoring the costs 
and cost structures associated with caring for people living with HIV and AIDS, as 
this would aid in planning and decision-making.
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OBJECTIVES: To evaluate economic impact of linezolid (LZD) versus vancomy-
cin (VAN) and teicoplanin (TEI) for treatment of confirmed methicillin-resistant 
Staphylococcus aureus (MRSA) nosocomial pneumonia (NP) in Brazilian private 
and public healthcare systems. METHODS: A 4 week decision model was developed 
capturing 1st and 2nd line therapy. Published literature, local sources, and expert 
opinion provided clinical and resource use data, such as efficacy, mortality, adverse 
events (AEs), treatment duration, and length of hospital/ICU stay. Brazil cost data 
was obtained from local published sources and micro-costing. Base-case analysis 
used 14-day treatment duration. In event of treatment failure/severe AEs on 1st-line 
therapy, drug was switched after 7 days. Costs were reported in 2014 Brazilian Real. 
Scenario based sensitivity analyses were conducted. RESULTS: From private per-
spective, LZD was associated with lower costs (by R$5,760 and R$10,551), and greater 
overall treatment success (by 2.7% and 13.3%) compared to VAN and TEI respectively, 
resulting in LZD ‘dominating’ both treatments. From public perspective, LZD costs 
